Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $25.51 USD
Change Today +1.18 / 4.85%
Volume 73.9K
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

paratek pharmaceuticals inc (PRTK) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/31/14 - $39.80
52 Week Low
10/24/14 - $11.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

paratek pharmaceuticals inc (PRTK) Related Bloomberg News

View More Bloomberg News

paratek pharmaceuticals inc (PRTK) Related Businessweek News

No Related Businessweek News Found

paratek pharmaceuticals inc (PRTK) Details

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

13 Employees
Last Reported Date: 04/24/15

paratek pharmaceuticals inc (PRTK) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $128.5K
President, Chief Medical Officer and Director
Total Annual Compensation: $488.8K
Chief Financial Officer and Secretary
Total Annual Compensation: $10.4K
Vice President of Research and Development
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2014.

paratek pharmaceuticals inc (PRTK) Key Developments

Paratek Pharmaceuticals, Inc. Approves Amendments to Amended and Restated Bylaws

On April 10, 2015, the Board of Directors of Paratek Pharmaceuticals, Inc. approved amendments to Amended and Restated Bylaws, or the New Bylaws, which supersede and replace prior Amended and Restated Bylaws, effective immediately. The New Bylaws, among other things, provide that: To be timely, written notice of nominations for election to the Board of Directors and proposals to be included in proxy materials, to be properly brought before an annual meeting by a stockholder, must be received at principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year’s annual meeting, notice by the stockholder must be received not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made; The Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on their behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against them arising pursuant to the Delaware General Corporation Law, certificate of incorporation or bylaws; or any action asserting a claim against the company that is governed by the internal affairs doctrine.

Paratek Pharmaceuticals, Inc. Announces Financial Results for the Year Ended December 31, 2014

Paratek Pharmaceuticals, Inc. announced financial results for the year ended December 31, 2014. For the year, the company reported a net loss of $19.8 million, or $7.82 per share, compared to a net loss of $11.4 million, or $185.13 per share, for the year ended December 31, 2013. Revenue in 2014 was $4.3 million, consisting of a $4.0 million milestone payment from Actavis Plc earned during the fourth quarter for the start of a Phase 3 clinical trial for sarecycline and recognition of $0.3 million in deferred revenue upon the termination of a collaborative research, development and commercialization agreement with a leading global animal health provider. Loss from operations was $17,835,000 compared to $7,540,000 a year ago.

Paratek Pharmaceuticals, Inc. announced delayed annual 10-K filing

On 03/31/2015, Paratek Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTK:US $25.51 USD +1.18

PRTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTK.
View Industry Companies

Industry Analysis


Industry Average

Valuation PRTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.5x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 79.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARATEK PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at